T3D Therapeutics, Inc.
Last verified 2026-05-08. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $2.5Mattributed |
|---|---|
| Latest round | grant, $2.5M, 2023-08-01attributed |
| Founded | 2013 |
| Headquarters | Research Triangle Park, North Carolina, USA |
| Industry | bio |
| Stage | unknown |
| Website | t3dtherapeutics.com |
T3D Therapeutics develops T3D-959, a metabolic disease-modifying drug for Alzheimer's and Huntington's disease. It serves patients with Alzheimer's and other neurodegenerative diseases tied to brain energy dysfunction. The first-in-class metabolic mechanism targets memory, motor function, and cognition simultaneously rather than amyloid plaques alone.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2023-08-01 | grant | $2.5M | undisclosed |
Detected tech stack
WordPress 6.7.5, FitVids.JS 4.27.6, Sucuri, jQuery Migrate 3.4.1, jQuery Mobile, Easy Pie Chart, PHP, MySQL, jquery 3.7.1
Provenance
| Fact | Status | Basis |
|---|---|---|
| Grant, $2.5M | attributed | sbir named as publisher. No document URL on file. |
| Total raised $2.5M | attributed | sbir named as publisher. No document URL on file. |
| Company existence | self-reported | t3dtherapeutics.com, read 2026-05-08 |
| Description | self-reported | t3dtherapeutics.com, read 2026-05-08 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.